ESC 2016

Episodes 1-16 of 19

Extra work of checking device data weekly does not translate into benefit for HF patient
Extra work of checking device data weekly does not translate into benefit for HF patient
ESC 2016
Extra work of checking device data weekly does not translate into benefit for HF patient
- Martin Cowie, MD
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
ESC 2016
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
- Dr. Brian Ference
Heart Failure news from ESC 2016 at a glance
Heart Failure news from ESC 2016 at a glance
ESC 2016
Heart Failure news from ESC 2016 at a glance
- Prof. Mariell Jessup
Epigenetics: A closer look at BET inhibition
Epigenetics: A closer look at BET inhibition
ESC 2016
Epigenetics: A closer look at BET inhibition
No indication for difference in efficacy between potent platelet inhibitors after PCI
No indication for difference in efficacy between potent platelet inhibitors after PCI
ESC 2016
No indication for difference in efficacy between potent platelet inhibitors after PCI
- Steen Dalby Kristensen, MD
Iron deficiency in the new HF guidelines
Iron deficiency in the new HF guidelines
ESC 2016
Iron deficiency in the new HF guidelines
- Peter van der Meer, MD
Heart failure news at the ESC
Heart failure news at the ESC
ESC 2016
Heart failure news at the ESC
- Frank Ruschitzka, MD
Would lower than the current ApoB targets be more useful for clinical decision-making?
Would lower than the current ApoB targets be more useful for clinical decision-making?
CSI 2016 ESC
Would lower than the current ApoB targets be more useful for clinical decision-making?
- Seth Shay Martin, MD
Targeting residual inflammatory risk as a strategy to lower CV risk
Targeting residual inflammatory risk as a strategy to lower CV risk
CSI 2016 ESC
Targeting residual inflammatory risk as a strategy to lower CV risk
- prof. Paul Ridker, MD
To SPRINT or not to SPRINT to a lower blood pressure target?
To SPRINT or not to SPRINT to a lower blood pressure target?
CSI 2016 ESC
To SPRINT or not to SPRINT to a lower blood pressure target?
Beyond statins: The role of ezetimibe in targeting residual risk
Beyond statins: The role of ezetimibe in targeting residual risk
ESC 2016
Beyond statins: The role of ezetimibe in targeting residual risk
- Chris Packard, MD
Interim results of new device for treatment resistant hypertension
Interim results of new device for treatment resistant hypertension
CSI 2016 ESC
Interim results of new device for treatment resistant hypertension
- Dr. Wilko Spiering
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
CSI 2016 ESC
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
- Prof. Silvio E Inzucchi
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
ESC 2016
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
- Erik Stroes, MD
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
ESC 2016
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
- John Kastelein, MD
A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?
A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?
ESC 2016
A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?
- Paul M Ridker, MD

1/2

Episodes 1-16 of 19

Title

Share on ReachMD